Romel Somwar

TL;DR: Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib, which should help guide the search for more effective therapy against a specific subset of lung cancers.

TL;DR: The data suggest that the type and nature of kinase inhibitor resistance mutations may be influenced by both anatomic site and mode of binding to the kinase target.

TL;DR: Predictive models of EGFR-mutant tumor behavior point to alternative drug dosing strategies to prevent and treat acquired resistance, and individual models based on the characteristics of diverse cancer cell types could offer clues for designing optimal treatment strategies.

TL;DR: The study met its primary endpoint, with confirmed partial responses seen in seven of 25 response-assessable patients, and defined RET rearrangements as actionable drivers in patients with lung cancers.

TL;DR: The present study is the first to show that globular adiponectin increases glucose uptake in skeletal muscle cells via GLUT4 translocation and subsequently reduces the rate of glycogen synthesis and shifts glucose metabolism toward lactate production.